Abstract

FARIA, Raquel et al. Window of Opportunity for Immunodulatory Therapy in COVID-19. Medicina Interna [online]. 2020, vol.27, suppl.1, pp.109-115. ISSN 0872-671X.  https://doi.org/10.24950/rspmi/P.Vista/COVID19/79/20/CHP/S/2020.

The COVID-19 pandemic is a serious public health problem worldwide, for which there is no effective therapies. About 20%-33% of patients are admitted to intensive care units and in these the mortality rate is higher than 25%. Death caused directly by the COVID-19 results, in most cases, from an inappropriate hyperinflammatory response to the infection, with the release of cytokines. Due to the parallelism with other immune-mediated inflammatory diseases, the authors made a critical review of the pathophysiological mechanisms involved and potential situations where the use of immunomodulators, in a narrow window of opportunity, may change the prognosis of some patients.

Keywords : Baricitinib; Coronavirus; Coronavirus Infection; Cytokines; Immunomodulation; Interleukin 1 Receptor Antagonist Protein; Steroids; Tocilizumab.

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )